Clinical Trial Update: LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LSALT Peptide versus placebo to prevent acute respiratory distress syndrome and acute kidney injury in COVID-19 patients has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Respiratory Distress Syndrome

Drugs mentioned

• LSALT peptide (LSALT peptide)

Snippet

Sponsor: Arch Biopartners Inc. | Conditions: COVID, Severe Acute Respiratory Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-07-09